Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395297 | 0.85 | RAB9A (0.49) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8130767 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8129293 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8130837 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL10494166 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8130917 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6550257 | 0.85 | RAB9A (0.46) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6398164 | 0.84 | DAO (0.53) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6900551 | 0.82 | RAB9A (0.58) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6402963 | 0.81 | MRGPRX4 (0.48) | RAB9ANPC1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | claimed |
| US-6552073-B1 | As anti-proliferative agent; for therapy of cancer | EXONHIT THERAPEUTICS SA (FR) | 2003-04-22 | — | — | US | claimed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| EP-1480966-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | Exonhit Therapeutics S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074508-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | EXONHIT THERAPEUTICS SA (FR) | 2003-09-12 | — | — | WO | disclosed |
| US-6552073-B1 | As anti-proliferative agent; for therapy of cancer | EXONHIT THERAPEUTICS SA (FR) | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | RAB9A 882/4885NPC1 151/4885CYP1A2 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.